To investigate the effects of PD-1 blockade on immune responses during cancer immunotherapy and to identify the population that could benefit from immunotherapy, we analyzed Th1/Th2 cytokines from the peripheral blood of 53 patients with NSCLC at baseline and at the first treatment evaluation, usually after two cycles of treatment. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.